It is announced today that BEBIG Medical has signed a MOU with Biobot Surgical to cooperate on providing a robotic-guided high dose rate (HDR) brachytherapy solution for prostate cancer treatment.

BEBIG Medical is a global provider of high quality radiation therapy products for cancer treatmen based in Germany with over 40 year’s experience in brachytherapy field and continus to provide affordable healthcare with proven clinical outcomes via strong and viable technology. 

Biobot Surgical is headquartered in Singapore and focuses on robotics-assisted percutaneous surgical systems. The company is expanding its core technology in precision needle positioning to address comprehensive prostate cancer care to improve patient prostate cancer outcomes.

Globally, prostate cancer is one of the most common cancer diagnosed in men and overall. HDR brachytherapy is a form of radiotherapy which involves a thin tube inserted into the prostate gland and a radiation source is then passed through the tube to kill the cancer cells. Traditionally, the ultrasound-guided HDR brachytherapy procedure uses a template grid for needle insertion into the prostate.

In this cooperation, BEBIG Medical will work with Biobot Surgical to apply iSR’s obot Mona Lisa 2.0, a robotics-assisted percutaneous surgical system, to automatically guides the needle insertion by a clinician to within 1.0mm* accuracy of the targeted needle position for treatment. The robotic arm allows flexibility of angulated needle trajectory for an optimal treatment plan and avoids critical anatomical structures.

“The future trend of medical device technology is moving towards digitalization, automation and artificial intelligence. The joint partnership is a vivid display of these orientations to achieve clinical excellence.” Said Mr. George Chan, Chairman and CEO of BEBIG Medical.

“BEBIG Medical is a well established brand in brachytherapy, while Biobot Surgical is known for its accurate placement of needles. The partnership enables our companies to bring robotics-assisted brachytherapy solutions to patients.” said Mr. Sim Kok Hwee, CEO of Biobot Surgical.

About Biobot Surgical Pte. Ltd.

Biobot Surgical is headquartered in Singapore and focuses on robotics-assisted percutaneous surgical systems. The company is expanding its core technology in precision needle positioning to address comprehensive prostate cancer care to improve patient prostate cancer outcomes. 

For more information: https://biobotsurgical.com/

About BEBIG Medical GmbH

BEBIG Medical GmbH (“BEBIG Medical”) is a global provider of high quality radiation therapy products for cancer treatment headquartered in Berlin, Germany. Preceded by the high dose brachytherapy business unit of Eckert & Ziegler AG, BEBIG Medical has a heritage of more than 40 years’ experience in brachytherapy field and continues to provide affordable healthcare with proven clinical outcomes via strong and viable technology. BEBIG Medical’s US subsidiary, Mick Radio-Nuclear Instruments, Inc., is also known internationally for its manufacturing expertise in the field of applicators and accessories to advance brachytherapy. With a team of professionals and offices in Europe, United States and Asia, the company is empowered to serve customers in more than 65 countries and regions together with a worldwide distribution network.

For more information: www.bebigmedical.com

Contact: Crystal Chen, Chief Commercial Officer, crystal.chen@bebigmedical.com